Clinical Trials Browser

Phase 2 × pembrolizumab × Other solid neoplasm × Clear all

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

NCT07098988 2026-05-13

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Phase 2 Recruiting

Other solid neoplasmThoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT02399371 2026-05-08

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Phase 2 Completed

65 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT04123366 2026-04-22

MK-7339-007

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT06006923 2026-01-20

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Phase 2 Terminated

GastrointestinalOther solid neoplasm

MSI-H Colorectal Cancer

NCT06155279 2026-01-13

CHIMERA

Phase 2 Active not recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05642780 2025-10-14

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT04914897 2025-10-02

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Phase 2 Terminated

106 enrolled 21 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 4 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06318286 2025-05-25

PENINSULA

Phase 2 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04171219 2025-05-16

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Phase 2 Terminated

31 enrolled 15 charts

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT04082572 2025-05-13

Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers

Phase 2 Completed

35 enrolled 10 charts

Other solid neoplasm

Locally Advanced Malignant Solid Neoplasm

NCT04287829 2024-11-05

PEMMELA

Phase 2 Active not recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05425576 2024-03-15

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Phase 2 Not yet recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03274661 2023-10-19

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Phase 2 Completed

52 enrolled 12 charts

Other solid neoplasm

Solid Tumor, Adult

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03644550 2021-12-02

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Phase 2 Terminated

18 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma

NCT05035381 2021-09-05

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

Phase 2 Unknown

GastrointestinalOther solid neoplasm

MSI-H Advanced Colorectal Cancer

NCT03175172 2019-04-04

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

Phase 2 Terminated

10 enrolled 11 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant